WO1998028978A1 - Structured glycerols and structured phosphatides - Google Patents
Structured glycerols and structured phosphatides Download PDFInfo
- Publication number
- WO1998028978A1 WO1998028978A1 PCT/US1997/007897 US9707897W WO9828978A1 WO 1998028978 A1 WO1998028978 A1 WO 1998028978A1 US 9707897 W US9707897 W US 9707897W WO 9828978 A1 WO9828978 A1 WO 9828978A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- compounds
- structured
- glycerol
- phosphatides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Definitions
- This invention relates to the field of chemical vehicles for delivering biologically active compounds to humans, mammals and other vertebrates, and methods of using the same. More specifically, this invention relates to chemical delivery vehicles for delivering biologically active compounds using esters of glycerol or glycerol phosphates, and methods of using the same.
- U.S. Patent No. 4,992,470 discloses a method of preventing muscle breakdown by administering free alpha- ketoisocapropic acid or pharmaceutically acceptable salts thereof to humans .
- Fatty acids have been used as carriers to deliver beneficial compounds to humans and other vertebrates.
- compositions utilizing fatty acids to solubilize drugs or steroids during administration have been developed (See U.S. Patent Nos . 4,148,308 and 4,340,594).
- U.S. Patent No. 4,528,197 discloses a method of enhancing protein anabolism by administering compositions of lipids, carbohydrates and lipids in an emulsion of triglycerides .
- Fatty acids by themselves may also provide specific health benefits.
- U.S. Patent No. 4,703,062 discloses a composition of medium and long chain triglycerides for administration to patients to treat diseases .
- Triglycerides in the form of structured lipids have also been developed as delivery vehicles for fatty acids.
- U.S. Patent No. 4,871,768 discloses structured lipids of omega-3 fatty acids and medium chain fatty acids.
- U.S. Patent Nos. 4,906,664 and 5,081,105 disclose such compositions for use in cancer treatment.
- U.S. Patent Nos. 4,607,052 and 4,847,296 disclose other triglyceride compositions of fatty acids.
- the type and size of the fatty acids in the structured lipid may vary.
- U.S. Patent No. 5,312,836 discloses a synthetic triglyceride of short and non-short chain fatty acids.
- U.S. Patent No. 4,952,606 discloses a composition of fatty acids and triglycerides formed by transesterification.
- U.S. Patent Nos. 4,703,062 and 4,753,963 disclose nutritional supplements and methods of using such supplements as sources of carbohydrates and amino acids. Structured lipids are administered with these components.
- compositions described above do not provide a common delivery system for different types of beneficial compounds.
- fatty acids when used as emulsions to deliver beneficial compounds, each of these compounds must be capable of forming an emulsion with the fatty acids. Once emulsified and ingested, each compound may be differentially absorbed; some compounds may be inefficiently absorbed during digestion.
- Another problem with such emulsions is that some beneficial compounds in free, purified form may irritate the digestive tract.
- U.S. Patent No. 5,583,198 discloses a composition of such beneficial substances linked to fats, including ethanolamine and tromethamine .
- This patent is incorporated by reference in its entirety.
- a disadvantage of such compositions is that the beneficial substances may not be readily cleaved from the fat carrier molecule.
- None of the patents discussed above disclose incorporating a composition for reversibly incorporating beneficial, biologically active compounds into chemical delivery vehicles to aid in the assimilation of those substances by human, other mammals and other vertebrates. There is a need for such delivery vehicles due to the inefficient absorption of many beneficial compounds during digestion. Additionally, many beneficial compounds are exhibit poor gastrointestinal tolerance. Beneficial substances also may be labile, such that they degrade before absorption.
- This invention relates to novel delivery vehicles for use in humans, mammals and other vertebrates to deliver biologically active compounds, including drugs, hormones, amino acids, organic acids, peptides, sugars, nucleotides, vitamins, minerals, mineral chelates, intermediary metabolites, and herbal compounds, hereafter described in generic terms in this application as Compounds. (The uncapitalized word compound is still used generically. )
- the composition of this invention includes esters of the above-named Compounds to glycerol or glycerol phosphatides, or their monoglyceride or diglyceride forms, to create a class of novel compounds called Structured Glycerols or Structured Phosphatides, respectively.
- the resultant structured forms are physically distinct from their components .
- Glycerols/Phosphatides ameliorate gastrointestinal side effects associated with oral administration of high doses of Compounds, improve uptake of Compounds into the lymphatic and portal systems (especially of lipid-soluble or insoluble Compounds) , improve solubility of Compounds otherwise insoluble, improve tolerability of oral administration of Compounds, provide a time-release or sustained release form of administration of Compounds, and provide improved stability of inherently labile Compounds, such as creatine, S-adenosyl-L-methionine (SAMe) , nicotinamide dinucleotide (NADH) , or L-glutamine.
- SAMe S-adenosyl-L-methionine
- NADH nicotinamide dinucleotide
- the invention thus described may be used for therapeutic purposes or enhancement of cellular processes in humans, other mammals and other vertebrates. It is an object of the invention to provide novel chemical vehicles, Structured Glycerols and Structured Phosphatides, for delivering biologically active Compounds to humans, mammals and other vertebrates .
- An advantage of the present invention is that Structured Glycerols provide alternate oral or injectable delivery methods for biologically active Compounds over the administration of non-esterified (free) Compounds.
- Glycerols are that they provide improved gastrointestinal tolerance, which increases the bioavailability of these compounds. Such improved bioavailability can sustain or prolonged the period of uptake. Another significant advantage is that Structured Glycerols can provide improved stability of Compounds which would otherwise be labile to water, during digestion or during uptake. Another object of the invented Structured Glycerols is to provide a delivery vehicle for specifically tailoring doses of desired Compounds to match clinical needs or storage requirements. An advantage of this invention is that high doses of single biologically active Compounds may be delivered to humans, mammals or other vertebrates. Another advantage is that controlled stoichiometric amounts of up to three different biologically active Compounds may be delivered to humans, mammals or other vertebrates.
- Yet another object of the invention is to provide a delivery vehicle for biologically active Compounds which are difficult to esterify to carbon hydroxyl groups.
- Biologically active Compounds may also be esterified to the phosphate groups of glycerol phosphate (s) to form
- Structured Phosphatides In addition to the advantages discussed above for Structured Glycerols, these Structured Phosphatides facilitate delivering a broader spectrum of biologically active Compounds to humans, mammals and other vertebrates.
- the present invention includes two novel classes of compounds, Structured Glycerols and Structured Phosphatides.
- Structured Glycerols have ester bonds between biologically active Compounds and the hydroxyl groups of glycerol and its monoglyceride or diglyceride derivatives.
- Structured Phosphatides include biologically active Compounds attached by ester bonds to the hydroxyl or phosphate groups of glycerol phosphatide and its monoglyceride or diglyceride derivatives.
- the biologically active Compounds within the scope of the present invention include, but are not limited to, drugs, hormones, amino acids, organic acids, peptides, sugars, nucleotides, vitamins, minerals, mineral chelates, intermediary metabolites, and herbal Compounds.
- Suitable drugs may include acetylsalicylate and acetaminophen.
- Suitable hormones may include melatonin and serotonin.
- Suitable amino acids may include the nineteen standard L- amino acids, proline, and non-standard amino acids such as hydroxyproline, selenomethionine, phosphoserine, L- carnithine and phospholeucine, as well as D-amino acids.
- Suitable organic acids may include pyruvate, lactate, alpha-keto-isocaproic acid and beta-hydroxy-beta- methylbutyric acid (HMB) .
- Nucleotides with the scope of the invention may include ribo- and deoxyribnucleotides, and phosphoadenosine phosphosulfate .
- Vitamins within the scope of the invention include vitamin A, niacin, other members of the vitamin B family, vitamins C, D, E, K, and cofactors including riboflavin, pantethine, pantetheine, pantothenic acid, pyridoxal (including phosphate forms) , biotin, thioredoxin, folates, and lipoic acid.
- Suitable sugars may include glucosamine.
- Minerals within the scope of the invention include copper, cobalt, iron, manganese, magnesium, selenium, and zinc.
- Suitable mineral chelates can include chelates of the minerals mentioned above as well as the copper salt of L-lysinate, the ferrous salt of glycinate, the zinc salt of L carnosinate and chromium picolinate salts.
- Suitable intermediary metabolites may include creatine, ornithine alpha-ketoglutarate, S- adenosyl-L-methionine, phosphoserine, phosphocholine, phosphoinositol, and phosphoethanolamine .
- Herbal components may include curcumin, ephedrine, caffeine, fumaric acid, cayenne, proanthocyanidin (s) , chlorophyll, and phylloquinone (s) .
- Glycerol is a ubiquitous molecule well-known as being the backbone of triglycerides, phospholipids, and other related compounds. Glycerol consists of a three carbon chain with a hydroxyl (alcohol) group on each carbon, and all other bonds being occupied with hydrogen (C 3 H 8 0 3 ) . The combination of an acid with a glycerol hydroxyl group results in an ester bond by the elimination of water (H 2 0) from the two precursor compounds. Similarly, acid groups can be esterified as a phosphate ester to the phosphate group on glycerol phosphatides.
- esters of glycerol and fatty acids are ever-present, and are termed glycerides (fats or oils) .
- Such glycerides may include mono-, di- and tri-glycerides .
- Phospholipid formation involves the substitution of a fatty acid on one end of the glycerol backbone with phosphoric acid (phosphate), forming a phosphatide.
- Other compounds can be esterified to the phosphate group, and commonly choline, serine, ethanolamine, and inositol are esterified to the phosphate to form the four known phospholipids.
- the other two hydroxyl sites on the phospholipid glycerol molecule are usually occupied by fatty acids or hydrogen atoms.
- the human body possesses extensive abilities to remove (hydrolyze) Compounds esterified to glycerol.
- triglycerides are solubilized by bile salts and digested by lipases to yield two fatty acids and one monoglyceride. These components are rapidly absorbed into intestinal enterocytes, reassembled into triglycerides, and delivered to the thoracic duct for transport into systemic circulation.
- phospholipids are digested similarly into lysophosphatides , and reassembled for transport inside gut enterocytes. Short- and medium-chain triglycerides can be transported directly to the liver by the portal route after intestinal absorption.
- Non-specific esterases present in intestinal lining cells, the liver, and all cells are capable of digesting any possible combination of esters found on glycerol backbones.
- NSEs Non-specific esterases
- the ubiquitous presence of high levels of phosphatases (both alkaline and acid phosphatases) in the intestinal lining and all cells is capable of hydrolyzing the bond between a Compound and the phosphate group of a Structured Phosphatide.
- a fatty acid may be esterified to the glycerol backbone .
- Suitable fatty acids may include oleic acid, eicosapentaenoic acid, alpha linolenic acid and valerenic acid. These acids can help solubilize the Structured Glycerol/Phosphatide and facilitate uptake during digestion.
- all of the Compounds on a Structured Glycerol/Phosphatide may be non-fatty acids. Since these groups are smaller and more hydrophilic than fatty acids on triglycerides, the potential for uptake of Structured Glycerol/Phosphatides in toto exists. Once inside gut enterocytes, hydrolysis by NSEs and phosphatases would release the Compounds attached to the glycerol or glycerol phosphate.
- the Structured Glycerol/Phosphatides can also act as emulsification agents themselves (similar to phospholipids) , improving concomitant uptake of other fatty components of the diet or of hydrolyzed Structured Glycerol/Phosphatides.
- Rl, R2 and R3 are independently selected from hydrogen, drugs, hormones, amino acids, organic acids, peptides, sugars, nucleotides, vitamins, minerals, mineral chelates, intermediary metabolites, and herbal compounds.
- Rl, R2 and R3 are attached to the glycerol backbone through an ester bond.
- the above formula shows the ester oxygen which is links the glycerol backbone and the R group .
- Rl, R2 and R3 are independently selected from hydrogen, drugs, hormones, amino acids, organic acids, peptides, sugars, nucleotides, vitamins, minerals, mineral chelates, intermediary metabolites, and herbal compounds.
- Rl, R2 and R3 are attached to the glycerol backbone through an ester bond or a phosphate ester bond.
- the above formula shows the ester oxygen which is shared between the glycerol (or glycerol phosphate) and the R group.
- one or more biologically active Compounds of the same type can be esterified to glycerol or glycerol phosphatide.
- the same or different amino acids could be esterified to glycerol or glycerol phosphatides.
- Glycerol/Phosphatide compound would include different types of biologically active Compounds.
- a fatty acid, an amino acid and a drug could be esterified to glycerol or glycerol phosphate .
- the invented Structured Glycerols/Phosphatides include dietary supplements, since each biologically active substance occurs naturally.
- one Structured Glycerol/Phosphatide would include an alpha tocopherol molecule attached at one hydroxyl, a fatty acid bound at the middle hydroxyl, and an amino acid bound to the phosphate group on the other end of the glycerol backbone.
- the Structured Glycerol/Phosphatide includes pharmaceuticals or drugs.
- An example of a pharmaceutical Structured Glycerol/Phosphatide would be a tetracycline antibiotic attached at one position of the glycerol backbone, a fatty acid at the central position, and a phosphoserine at the third position.
- the identity of biologically active Compounds on Structured Glycerol/Phosphatides can be manipulated to deliver desired Compounds found to be efficacious for repletion or treatment of health conditions .
- the invented Structured Glycerols and Phosphatides can also provide improved stability of biologically active Compounds which would otherwise be labile to water, during digestion or during uptake.
- biologically active Compounds which would otherwise be labile to water, during digestion or during uptake.
- creatine, S-adenosyl-L-methionine (SAMe) , nicotinamide dinucleotide (NADH) , and L-glutamine are typically labile and unavailable for absorption during digestion.
- SAMe S-adenosyl-L-methionine
- NADH nicotinamide dinucleotide
- L-glutamine are typically labile and unavailable for absorption during digestion.
- Table One illustrates various embodiments of Structured Glycerols/Phosphatides. Although separate Compounds are listed as attached to different positions on the glycerol backbone, the order may be varied without affecting the Proposed Use. Likewise, a mixture of three different Structured Glycerols/Phosphatides, each containing only one compound could be mixed together in equimolar amounts to achieve the same delivery of Compounds as listed in the Table. Table 1. Partial List of Proposed Uses for Specific Structured Glycerols/Phosphatides
- A L-Lysinate, copper salt Rheumatoid arthritis,
- the invented Structured Glycerols/Phosphatides may be used for therapeutic purposes or enhancement of cellular processes in humans and mammals for delivery of Compounds by oral or injectable means.
- suitable doses of the Structured Glycerols and Phosphatides will vary according to the particular Compounds esterified to that vehicle. The appropriate dosages will be readily determinable by those in the art, according to the composition of the specific Structured Glycerol/Phosphatide.
- Glycerols/Phosphatides may be manufactured by numerous methods, as will be appreciated by those of skill in the art.
- these delivery vehicles are enzymatically synthesized.
- Compounds could be attached nonspecific esterases in the presence of a stoichiometric excess of selected Compounds over glycerol or glycerol phosphate or mono- or di- glyceride forms thereof.
- Compounds can be covalently linked to the phosphate moiety of glycerol phosphate using reversible phosphatases .
- Glycerols and Phosphatides may be synthesized using chemical means. Such means for chemically forming esters bonds are known in the art. For example, the Kirk-Othmer Encyclopedia of Chemical Technology (4 th ed., 1991) discloses methods for esterification for different types of organic esters. (This reference is incorporated by reference) .
- Amino acids and other Compounds can be esterified to glycerol or glycerol phosphate under acidic conditions. Suitable acids may include strong acids such as sulfuric, hydrochloric or phosphoric acids and ⁇ Lewis acids. As will be appreciated by those of skill in the art, strong acids are only suitable for Compounds which are stable under strongly acidic conditions.
- glutamine and asparagine will be labile under strongly acidic conditions.
- Another method of chemical synthesis includes acid-regenerated cation-exchange resins. Such resins may be periodically charged and regenerated, but are also suitable for use in continuous processes .
- Esters of Structured Glycerols and Phosphatides may also be formed using other methods of chemical synthesis.
- esters between glycerol hydroxyl groups and Components can be formed using acid anhydrides or acid chlorides of the Components.
- amide, nitrile, ether aldehyde, ketone and even alcohol groups of the Compounds or derivatives of the Compounds can be covalently attached to glycerol or glycerol phosphatides under the appropriate conditions to form ester bonds.
- Glycerol is commercially available from numerous sources. Glycerols are preferably of food grade quality. Glycerol phosphate is also readily available from commercial sources or may be synthesized using phosphorylating enzymes such as glycerol kinase . Derivatives of glycerol, including mono- and di -glycerides, and glycerol phosphates, such as mono- and di-phosphatides, containing fatty acids are also commercially available from numerous sources, such as Sigma Chemical Company, Aldrich Chemical Company.
- the Structured Glycerol/Phosphatide may be purified using numerous purification schemes, including distillation, reactive extraction, reverse osmosis and chromatography . Heat distillation is preferred for stable Compounds which will not degrade under those conditions . Evaporative distillation may be suitable for volatile Structured Glycerols/Phosphatides. Reverse osmosis is preferred for larger Structured Glycerols and Phosphatides, especially when they are separated from smaller molecular weight, non- esterified Compounds.
- chromatography particularly bulk column chromatography, HPLC, FPLC and similar methods are suitable for obtaining high quality separations of the Structured Glycerols/Phosphatides from the unreacted Compounds or side reactions formed during the esterification.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU31207/97A AU3120797A (en) | 1996-05-08 | 1997-05-08 | Structured glycerols and structured phosphatides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64653396A | 1996-05-08 | 1996-05-08 | |
US08/646,533 | 1996-05-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998028978A1 true WO1998028978A1 (en) | 1998-07-09 |
Family
ID=24593411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/007897 WO1998028978A1 (en) | 1996-05-08 | 1997-05-08 | Structured glycerols and structured phosphatides |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3120797A (en) |
WO (1) | WO1998028978A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034298A1 (en) * | 1998-12-04 | 2000-06-15 | Herbert Schott | Glyceryl nucleotides, method for the production thereof and their use |
EP1550651A1 (en) * | 2002-09-26 | 2005-07-06 | Kyowa Hakko Kogyo Co., Ltd. | Glycerol derivative |
WO2007071733A3 (en) * | 2005-12-21 | 2007-09-07 | Proyecto Empresarial Brudy Sl | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
ES2315125A1 (en) * | 2005-12-21 | 2009-03-16 | Proyecto Empresarial Brudy, S.L. | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
ITUB20159393A1 (en) * | 2015-12-22 | 2017-06-22 | Univ Degli Studi Di Milano Bicocca | New compounds for the capture of carbon dioxide from gaseous mixtures and subsequent release, relative process and plant |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
-
1997
- 1997-05-08 AU AU31207/97A patent/AU3120797A/en not_active Abandoned
- 1997-05-08 WO PCT/US1997/007897 patent/WO1998028978A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US5607691A (en) * | 1992-06-12 | 1997-03-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787525B1 (en) | 1998-12-04 | 2004-09-07 | Herbert Schott | Glyceryl nucleotides, method for the production thereof and their use |
WO2000034298A1 (en) * | 1998-12-04 | 2000-06-15 | Herbert Schott | Glyceryl nucleotides, method for the production thereof and their use |
US7569706B2 (en) | 2002-09-26 | 2009-08-04 | Kyowa Hakko Kirin Co., Ltd. | Glycerol derivative |
EP1550651A1 (en) * | 2002-09-26 | 2005-07-06 | Kyowa Hakko Kogyo Co., Ltd. | Glycerol derivative |
EP1550651A4 (en) * | 2002-09-26 | 2006-06-14 | Kyowa Hakko Kogyo Kk | Glycerol derivative |
WO2007071733A3 (en) * | 2005-12-21 | 2007-09-07 | Proyecto Empresarial Brudy Sl | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
CN101346138B (en) * | 2005-12-21 | 2013-03-13 | 布鲁迪科技有限公司 | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
JP2009523414A (en) * | 2005-12-21 | 2009-06-25 | ブルーディ、テクノロジー、ソシエダッド、リミターダ | Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells |
ES2315125A1 (en) * | 2005-12-21 | 2009-03-16 | Proyecto Empresarial Brudy, S.L. | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
AU2006327064B2 (en) * | 2005-12-21 | 2012-04-26 | Brudy Technology, S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
US10493008B2 (en) | 2005-12-21 | 2019-12-03 | Brudy Technology, S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
US9265745B2 (en) | 2005-12-21 | 2016-02-23 | Brudy Technology S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
ES2316263A1 (en) * | 2005-12-21 | 2009-04-01 | Proyecto Empresarial Brudy, S.L. | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
US9259408B2 (en) | 2005-12-21 | 2016-02-16 | Brudy Technology S.L. | Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage |
JP2014028830A (en) * | 2005-12-21 | 2014-02-13 | Brudy Technology Sl | Use of dha, epa or dha-derived epa for treating pathology associated with cellular oxidative damage |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8545896B2 (en) | 2011-09-29 | 2013-10-01 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
ITUB20159393A1 (en) * | 2015-12-22 | 2017-06-22 | Univ Degli Studi Di Milano Bicocca | New compounds for the capture of carbon dioxide from gaseous mixtures and subsequent release, relative process and plant |
Also Published As
Publication number | Publication date |
---|---|
AU3120797A (en) | 1998-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991016920A1 (en) | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs | |
US5434183A (en) | Phospholipids containing omega-3-fatty acids | |
US8633253B2 (en) | Omega-3 diglyceride emulsions | |
US5436269A (en) | Method for treating hepatitis | |
US20050130937A1 (en) | Lipids containing omega-3 and omega-6 fatty acids | |
US20030232097A1 (en) | Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen | |
JP5283659B2 (en) | Methyl donor salt or complex salt with phytic acid or derivatives thereof, and synthesis method thereof | |
CN1679532A (en) | Therapeutic and dietary compositions | |
EP1414470B1 (en) | Micronutrient phosphates as dietary and health supplements | |
US8252836B2 (en) | Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease | |
TW317500B (en) | ||
EP0217920B1 (en) | Composition for delivery of orally administered substances | |
WO2006067498A1 (en) | Eicosapentaenoic acid for the treatment of cancer | |
JPH06256179A (en) | Learning ability improver | |
WO1998028978A1 (en) | Structured glycerols and structured phosphatides | |
CN112933046A (en) | Adriamycin prodrug active drug-loaded liposome and preparation method and application thereof | |
US20070009590A1 (en) | Physiologically active composition based on phosphatidylserine | |
CN106798735B (en) | Hydrophilic small molecule brain-targeted secondary delivery medicine carrier and preparation method thereof | |
JP4700193B2 (en) | Methods and compositions for increasing intestinal absorption of fat | |
US20020172710A1 (en) | Clinical use of liposome technology for the delivery of nutrients to patients with the short bowel syndrome | |
US4626527A (en) | Process for utilizing choline to sustain muscular performance | |
JPH0667833B2 (en) | Enteral nutrition | |
JP2941787B2 (en) | Pharmaceutical composition and health food containing polyunsaturated fatty acid | |
WO2018115459A1 (en) | Omega-3 fatty acid composition for preventing and/or treating cachexia | |
WO2007057090A1 (en) | A combination comprising squalene, a phospholipid and an omega 3 fatty acid for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09180654 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98529964 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |